Hypoxia-driven selection of the metastatic phenotype

Cancer and Metastasis Reviews

Volumn 26, Issue 2, 2007, Pages 319-331

  Sullivan, Richard ^a   Graham, Charles H ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

HIF; Hypoxia; Invasion; Metastasis; Selection

Indexed keywords

INTEGRIN; NERVE CELL ADHESION MOLECULE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UROKINASE RECEPTOR; UVOMORULIN; VASCULOTROPIN;

ANOIKIS; BASEMENT MEMBRANE; BLOOD VESSEL PERMEABILITY; CANCER INVASION; CELL MIGRATION; CELL MOTILITY; CELL POPULATION; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME REPRESSION; EPITHELIUM; EXTRACELLULAR MATRIX; EXTRAVASATION; GENETIC REGULATION; GENETIC SELECTION; HUMAN; HYPOXIA; LYMPH FLOW; LYMPHANGIOGENESIS; MESENCHYME; METASTASIS; MICROCIRCULATION; MICROENVIRONMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; STROMA; TUMOR CELL; TUMOR VASCULARIZATION;

ACCLIMATIZATION; CELL HYPOXIA; CELL MOVEMENT; HUMANS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PHENOTYPE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34547107592     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-007-9062-2     Document Type: Review

References (149)

1. Thomlinson, R. H., & Gray, L. H. (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. British Journal of Cancer, 9, 539-549.
2. Brown, J. M., & Wilson, W. R. (2004). Exploiting tumour hypoxia in cancer treatment. Nature Reviews. Cancer, 4, 437-447.
3. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., & Vaupel, P. (1996). Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research, 56, 4509-4515.
4. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R., et al. (1996). Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Research, 56, 941-943.
5. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., & Dewhirst, M. W. (1997). Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. International Journal of Radiation Oncology, Biology, Physics, 38, 285-289.
6. Lartigau, E., Randrianarivelo, H., Avril, M. F., Margulis, A., Spatz, A., Eschwege, F., et al. (1997). Intratumoral oxygen tension in metastatic melanoma. Melanoma Research, 7, 400-406.
7. Movsas, B., Chapman, J. D., Greenberg, R. E., Hanlon, A. L., Horwitz, E. M., Pinover, W. H., et al. (2000). Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: An Eppendorf pO(2) study. Cancer, 89, 2018-2024.
8. Movsas, B., Chapman, J. D., Horwitz, E. M., Pinover, W. H., Greenberg, R. E., Hanlon, A. L., et al. (1999). Hypoxic regions exist in human prostate carcinoma. Urology, 53, 11-18.
9. Hill, R. P. (1990). Tumor progression: Potential role of unstable genomic changes. Cancer Metastasis Reviews, 9, 137-147.
10. Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991). Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. New England Journal of Medicine, 324, 1-8.
11. Weidner, N. (1993). Tumor angiogenesis: Review of current applications in tumor prognostication. Seminars in Diagnostic Pathology, 10, 302-313.
12. Hockel, M., Schlenger, K., Hockel, S., & Vaupel, P. (1999). Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Research, 59, 4525-4528.
13. Sundfor, K., Lyng, H., & Rofstad, E. K. (1998). Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. British Journal of Cancer, 78, 822-827.
14. Young, S. D., Marshall, R. S., & Hill, R. P. (1988). Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 85, 9533-9537.
15. Young, S. D., & Hill, R. P. (1990). Effects of reoxygenation on cells from hypoxic regions of solid tumors: Anticancer drug sensitivity and metastatic potential. Journal of the National Cancer Institute, 82, 371-380.
16. Cairns, R. A., Kalliomaki, T., & Hill, R. P. (2001). Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Research, 61, 8903-8908.
17. Postovit, L. M., Adams, M. A., Lash, G. E., Heaton, J. P., & Graham, C. H. (2002). Oxygen-mediated regulation of tumor cell invasiveness. Involvement of a nitric oxide signaling pathway. Journal of Biological Chemistry, 277, 35730-35737.
18. Rofstad, E. K., Rasmussen, H., Galappathi, K., Mathiesen, B., Nilsen, K., & Graff, B. A. (2002). Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Research, 62, 1847-1853.
19. Gatenby, R. A., & Gillies, R. J. (2004). Why do cancers have high aerobic glycolysis? Nature Reviews. Cancer, 4, 891-899.
20. Jiang, B. H., Agani, F., Passaniti, A., & Semenza, G. L. (1997). V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. Cancer Research, 57, 5328-5335.
21. Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., et al. (1997). Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 94, 8104-8109.
22. Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Reviews. Cancer, 3, 721-732.
23. Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences of the United States of America, 92, 5510-5514.
24. Cockman, M. E., Masson, N., Mole, D. R., Jaakkola, P., Chang, G. W., Clifford, S. C., et al. (2000). Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. Journal of Biological Chemistry, 275, 25733-25741.
25. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399, 271-275.
26. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002). Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science, 295, 858-861.
27. Hirota, K., & Semenza, G. L. (2005). Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochemical and Biophysical Research Communications, 338, 610-616.
28. Harris, A. L. (2002). Hypoxia-A key regulatory factor in tumour growth. Nature Reviews. Cancer, 2, 38-47.
29. Royds, J. A., Dower, S. K., Qwarnstrom, E. E., & Lewis, C. E. (1998). Response of tumour cells to hypoxia: Role of p53 and NFkB. Molecular Pathology, 51, 55-61.
30. Damert, A., Ikeda, E., & Risau, W. (1997). Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochemical Journal, 327(Pt 2), 419-423.
31. Yamashita, K., Discher, D. J., Hu, J., Bishopric, N. H., & Webster, K. A. (2001). Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. Journal of Biological Chemistry, 276, 12645-12653.
32. Kimura, H., Weisz, A., Kurashima, Y., Hashimoto, K., Ogura, T., D'Acquisto, F., et al. (2000). Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: Control of hypoxia-inducible factor-1 activity by nitric oxide. Blood, 95, 189-197.
33. Norris, M. L., & Millhorn, D. E. (1995). Hypoxia-induced protein binding to O2-responsive sequences on the tyrosine hydroxylase gene. Journal of Biological Chemistry, 270, 23774-23779.
34. Michiels, C., Minet, E., Michel, G., Mottet, D., Piret, J. P., & Raes, M. (2001). HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: Role of MAP kinases. IUBMB Life, 52, 49-53.
35. Seta, K. A., Spicer, Z., Yuan, Y., Lu, G., & Millhorn, D. E. (2002). Responding to hypoxia: Lessons from a model cell line. Science's Signal Transduction Knowledge Environment, 2002, RE11.
36. Richard, D. E., Berra, E., Gothie, E., Roux, D., & Pouyssegur, J. (1999). p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. Journal of Biological Chemistry, 274, 32631-32637.
37. Brader, S., & Eccles, S. A. (2004). Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori, 90, 2-8.
38. Simon, M. C. (2006). Mitochondrial reactive oxygen species are required for hypoxic HIF alpha stabilization. Advances in Experimental Medicine and Biology, 588, 165-170.
39. Guzy, R. D., & Schumacker, P. T. (2006). Oxygen sensing by mitochondria at complex III: The paradox of increased reactive oxygen species during hypoxia. Experimental Physiology, 91, 807-819.
40. Liu, Y., Christou, H., Morita, T., Laughner, E., Semenza, G. L., & Kourembanas, S. (1998). Carbon monoxide and nitric oxide suppress the hypoxic induction of vascular endothelial growth factor gene via the 5′ enhancer. Journal of Biological Chemistry, 273, 15257-15262.
41. Huang, L. E., Willmore, W. G., Gu, J., Goldberg, M. A., & Bunn, H. F. (1999). Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. Journal of Biological Chemistry, 274, 9038-9044.
42. Postovit, L. M., Sullivan, R., Adams, M. A., & Graham, C. H. (2005). Nitric oxide signalling and cellular adaptations to changes in oxygenation. Toxicology, 208, 235-248.
43. Bienz, M. (2005). Beta-catenin: A pivot between cell adhesion and Wnt signalling. Current Biology, 15, R64-R67.
44. Graff, J. R., Gabrielson, E., Fujii, H., Baylin, S. B., & Herman, J. G. (2000). Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. Journal of Biological Chemistry, 275, 2727-2732.
45. Krishnamachary, B., Zagzag, D., Nagasawa, H., Rainey, K., Okuyama, H., Baek, J. H., et al. (2006). Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Research, 66, 2725-2731.
46. Imai, T., Horiuchi, A., Wang, C., Oka, K., Ohira, S., Nikaido, T., et al. (2003). Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. American Journal of Pathology, 163, 1437-1447.
47. Bates, R. C., & Mercurio, A. M. (2005). The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biotherapy, 4, 365-370.
48. Kurrey, N. K. K. A., & Bapat, S. A. (2005). Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecologic Oncology, 97, 155-165.
49. Esteban, M. A., Tran, M. G., Harten, S. K., Hill, P., Castellanos, M. C., Chandra, A., et al. (2006). Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Research, 66, 3567-3575.
50. Luo, Y., He, D. L., Ning, L., Shen, S. L., Li, L., & Li, X. (2006). Hypoxia-inducible factor-1alpha induces the epithelial-mesenchymal transition of human prostatecancer cells. Chinese Medical Journal (English), 119, 713-718.
51. Cano, A., Perez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., et al. (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biology, 2, 76-83.
52. Tsutsumi, S., Yanagawa, T., Shimura, T., Kuwano, H., & Raz, A. (2004). Autocrine motility factor signaling enhances pancreatic cancer metastasis. Clinical Cancer Research, 10, 7775-7784.
53. Barrallo-Gimeno, A., & Nieto, M. A. (2005). The Snail genes as inducers of cell movement and survival: Implications in development and cancer. Development, 132, 3151-3161.
54. Li, G., Satyamoorthy, K., & Herlyn, M. (2001). N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Research, 61, 3819-3825.
55. Kuphal, S., & Bosserhoff, A. K. (2006). Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma. Oncogene, 25, 248-259.
56. Kuphal, S., Poser, I., Jobin, C., Hellerbrand, C., & Bosserhoff, A. K. (2004). Loss of E-cadherin leads to upregulation of NF-kappaB activity in malignant melanoma. Oncogene, 23, 8509-8519.
57. Huber, M. A., Beug, H., & Wirth, T. (2004). Epithelial-mesenchymal transition: NF-kappaB takes center stage. Cell Cycle, 3, 1477-1480.
58. Huber, M. A., Azoitei, N., Baumann, B., Grunert, S., Sommer, A., Pehamberger, H., et al. (2004). NF-kappaB is essential for epithelial- mesenchymal transition and metastasis in a model of breast cancer progression. Journal of Clinical Investigation, 114, 569-581.
59. Yebra, M., Parry, G. C., Stromblad, S., Mackman, N., Rosenberg, S., Mueller, B. M., et al. (1996). Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. Journal of Biological Chemistry, 271, 29393-29399.
60. Waltz, D. A., & Chapman, H. A. (1994). Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. Journal of Biological Chemistry, 269, 14746-14750.
61. Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V., et al. (1996). Regulation of integrin function by the urokinase receptor. Science, 273, 1551-1555.
62. Pyke, C., Kristensen, P., Ralfkiaer, E., Grondahl-Hansen, J., Eriksen, J., Blasi, F., et al. (1991). Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. American Journal of Pathology, 138, 1059-1067.
63. Duffy, M. J., Maguire, T. M., McDermott, E. W., & O'Higgins, N. (1999). Urokinase plasminogen activator: A prognostic marker in multiple types of cancer. Journal of Surgical Oncology, 71, 130-135.
64. Schmitt, M., Harbeck, N., Thomssen, C., Wilhelm, O., Magdolen, V., Reuning, U., et al. (1997). Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy. Thrombosis and Haemostasis, 78, 285-296.
65. Kobayashi, H., Fujishiro, S., & Terao, T. (1994). Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Research, 54, 6539-6548.
66. Riethdorf, L., Riethdorf, S., Petersen, S., Bauer, M., Herbst, H., Janicke, F., et al. (1999). Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix. Journal of Pathology, 189, 245-250.
67. Yang, J. L., Seetoo, D., Wang, Y., Ranson, M., Berney, C. R., Ham, J. M., et al. (2000). Urokinase-type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. International Journal of Cancer, 89, 431-439.
68. Graham, C. H., Forsdike, J., Fitzgerald, C. J., & Macdonald-Goodfellow, S. (1999). Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. International Journal of Cancer, 80, 617-623.
69. Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., et al. (2003). Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Research, 63, 1138-1143.
70. Rofstad, E. K., Mathiesen, B., Henriksen, K., Kindem, K., & Galappathi, K. (2005). The tumor bed effect: Increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. Cancer Research, 65, 2387-2396.
71. Graham, C. H., Fitzpatrick, T. E., & McCrae, K. R. (1998). Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood, 91, 3300-3307.
72. Maity, A., & Solomon, D. (2000). Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia. Experimental Cell Research, 255, 250-257.
73. Yoon, S. Y., Lee, Y. J., Seo, J. H., Sung, H. J., Park, K. H., Choi, I. K., et al. (2006). uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line. Cell Research, 16, 75-81.
74. Lee, K. H., Choi, E. Y., Hyun, M. S., & Kim, J. R. (2004). Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4. Experimental and Molecular Medicine, 36, 57-64.
75. Zagzag, D., Zhong, H., Scalzitti, J. M., Laughner, E., Simons, J. W., & Semenza, G. L. (2000). Expression of hypoxia-inducible factor 1alpha in brain tumors: Association with angiogenesis, invasion, and progression. Cancer, 88, 2606-2618.
76. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., et al. (1999). Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Research, 59, 5830-5835.
77. Trusolino, L., & Comoglio, P. M. (2002). Scatter-factor and semaphorin receptors: Cell signalling for invasive growth. Nature Reviews. Cancer, 2, 289-300.
78. Longati, P., Albero, D., & Comoglio, P. M. (1996). Hepatocyte growth factor is a pleiotropic factor protecting epithelial cells from apoptosis. Cell Death and Differentiation, 3, 23-28.
79. Amicone, L., Spagnoli, F. M., Spath, G., Giordano, S., Tommasini, C., Bernardini, S., et al. (1997). Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. EMBO Journal, 16, 495-503.
80. Grotegut, S., von Schweinitz, D., Christofori, G., & Lehembre, F. (2006). Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO Journal, 25, 3534-3545.
81. Trusolino, L., Cavassa, S., Angelini, P., Ando, M., Bertotti, A., Comoglio, P. M., et al. (2000). HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB Journal, 14, 1629-1640.
82. Ghoussoub, R. A., Dillon, D. A., D'Aquila, T., Rimm, E. B., Fearon, E. R., & Rimm, D. L. (1998). Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer, 82, 1513-1520.
83. Camp, R. L., Rimm, E. B., & Rimm, D. L. (1999). Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer, 86, 2259-2265.
84. Di Renzo, M. F., Olivero, M., Ferro, S., Prat, M., Bongarzone, I., Pilotti, S., et al. (1992). Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene, 7, 2549-2553.
85. Liu, C., Park, M., & Tsao, M. S. (1992). Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene, 7, 181-185.
86. Di Renzo, M. F., Olivero, M., Giacomini, A., Porte, H., Chastre, E., Mirossay, L., et al. (1995). Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clinical Cancer Research, 1, 147-154.
87. Martinez-Rumayor, A., Arrieta, O., Guevara, P., Escobar, E., Rembao, D., Salina, C., et al. (2004). Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas. Cancer Letter, 213, 117-124.
88. Kawano, R., Ohshima, K., Karube, K., Yamaguchi, T., Kohno, S., Suzumiya, J., et al. (2004). Prognostic significance of hepatocyte growth factor and c-MET expression in patients with diffuse large B-cell lymphoma. British Journal of Haematology, 127, 305-307.
89. Tsukinoki, K., Yasuda, M., Mori, Y., Asano, S., Naito, H., Ota, Y., et al. (2004). Hepatocyte growth factor and c-Met immunoreactivity are associated with metastasis in high grade salivary gland carcinoma. Oncology Reports, 12, 1017-1021.
90. Rong, S., Segal, S., Anver, M., Resau, J. H., & Vande Woude, G. F. (1994). Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proceedings of the National Academy of Sciences of the United States of America, 91, 4731-4735.
91. Meiners, S., Brinkmann, V., Naundorf, H., & Birchmeier, W. (1998). Role of morphogenetic factors in metastasis of mammary carcinoma cells. Oncogene, 16, 9-20.
92. Jeffers, M., Fiscella, M., Webb, C. P., Anver, M., Koochekpour, S., Vande Woude, G. F. (1998). The mutationally activated Met receptor mediates motility and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 95, 14417-14422.
93. Oh, R. R., Park, J. Y., Lee, J. H., Shin, M. S., Kim, H. S., Lee, S. K., et al. (2002). Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas. APMIS, 110, 229-238.
94. Koochekpour, S., Jeffers, M., Wang, P. H., Gong, C., Taylor, G. A., Roessler, L. M., et al. (1999). The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Molecular and Cellular Biology, 19, 5902-5912.
95. Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., & Klausner, R. D. (2002). The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cells, 1, 247-255.
96. Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cells, 3, 347-361.
97. Chen, H. H., Su, W. C., Lin, P. W., Guo, H. R., & Lee, W. Y. (2006). Hypoxia-inducible factor-1alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Research and Treatment.
98. Scarpino, S., Cancellario, dF., Di Napoli, A., Pasquini, A., Marzullo, A., & Ruco, L. P. (2004). Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. Journal of Pathology, 202, 352-358.
99. Ide, T., Kitajima, Y., Miyoshi, A., Ohtsuka, T., Mitsuno, M., Ohtaka, K., et al. (2006). Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. International Journal of Cancer, 119, 2750-2759.
100. Hara, S., Nakashiro, K., Klosek, S. K., Ishikawa, T., Shintani, S., & Hamakawa, H. (2006). Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. Oral Oncology, 42, 593-598.
101. Boccaccio, C., Gaudino, G., Gambarotta, G., Galimi, F., & Comoglio, P. M. (1994). Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. Journal of Biological Chemistry, 269, 12846-12851.
102. Tacchini, L., Dansi, P., Matteucci, E., & Desiderio, M. A. (2001). Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis, 22, 1363-1371.
103. Tacchini, L., Matteucci, E., De Ponti, C., & Desiderio, M. A. (2003). Hepatocyte growth factor signaling regulates transactivation of genes belonging to the plasminogen activation system via hypoxia inducible factor-1. Experimental Cell Research, 290, 391-401.
104. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 219, 983-985.
105. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., & Ferrara, N. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 246, 1306-1309.
106. Toi, M., Kondo, S., Suzuki, H., Yamamoto, Y., Inada, K., Imazawa, T., et al. (1996). Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer, 77, 1101-1106.
107. Wong, M. P., Cheung, N., Yuen, S. T., Leung, S. Y., & Chung, L. P. (1999). Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. International Journal of Cancer, 81, 845-850.
108. Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., & Ellis, L. M. (1995). Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Research, 55, 3964-3968.
109. Toi, M., Hoshina, S., Takayanagi, T., & Tominaga, T. (1994). Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Japanese Journal of Cancer Research, 85, 1045-1049.
110. Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 359, 843-845.
111. Minchenko, A., Salceda, S., Bauer, T., & Caro, J. (1994). Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cellular & Molecular Biology Research, 40, 35-39.
112. Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., et al. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology, 16, 4604-4613.
113. Levy, A. P., Levy, N. S., & Goldberg, M. A. (1996). Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. Journal of Biological Chemistry, 271, 2746-2753.
114. Mizukami, Y., Li, J., Zhang, X., Zimmer, M. A., Iliopoulos, O., & Chung, D. C. (2004). Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Research, 64, 1765-1772.
115. Shinojima, T., Oya, M., Takayanagi, A., Mizuno, R., Shimizu, N., & Murai, M. (2007). Renal cancer cells lacking hypoxia inducible factor (HIF)-1{alpha} expression maintain vascular endothelial growth factor expression through HIF-2{alpha}. Carcinogenesis, 28(3), 529-536.
116. Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., et al. (1998). Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature, 394, 485-490.
117. Ryan, H. E., Lo, J., & Johnson, R. S. (1998). HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO Journal, 17, 3005-3015.
118. Dvorak, H. F., Nagy, J. A., Feng, D., Brown, L. F., & Dvorak, A. M. (1999). Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Current Topics in Microbiology and Immunology, 237, 97-132.
119. Rofstad, E. K., Tunheim, S. H., Mathiesen, B., Graff, B. A., Halsor, E. F., Nilsen, K., et al. (2002). Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. Cancer Research, 62, 661-664.
120. Jain, R. K. (1998). The next frontier of molecular medicine: Delivery of therapeutics. Nature Medicine, 4, 655-657.
121. Leu, A. J., Berk, D. A., Lymboussaki, A., Alitalo, K., & Jain, R. K. (2000). Absence of functional lymphatics within a murine sarcoma: A molecular and functional evaluation. Cancer Research, 60, 4324-4327.
122. Padera, T. P., Kadambi, A., di Tomaso, E., Carreira, C. M., Brown, E. B., Boucher, Y., et al. (2002). Lymphatic metastasis in the absence of functional intratumor lymphatics. Science, 296, 1883-1886.
123. Boucher, Y., Lee, I., & Jain, R. K. (1995). Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. Microvascular Research, 50, 175-182.
124. Dadiani, M., Kalchenko, V., Yosepovich, A., Margalit, R., Hassid, Y., Degani, H., et al. (2006). Real-time imaging of lymphogenic metastasis in orthotopic human breast cancer. Cancer Research, 66, 8037-8041.
125. Dadiani, M., Margalit, R., Sela, N., & Degani, H. (2004). High-resolution magnetic resonance imaging of disparities in the transcapillary transfer rates in orthotopically inoculated invasive breast tumors. Cancer Research, 64, 3155-3161.
126. Nathanson, S. D. (2003). Insights into the mechanisms of lymph node metastasis. Cancer, 98, 413-423.
127. Fyles, A., Milosevic, M., Pintilie, M., Syed, A., Levin, W., Manchul, L., et al. (2006). Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancer. Radiotherapy and Oncology, 80, 132-137.
128. Claffey, K. P., Brown, L. F., del Aguila, L. F., Tognazzi, K., Yeo, K. T., Manseau, E. J., et al. (1996). Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Research, 56, 172-181.
129. Esser, S., Lampugnani, M. G., Corada, M., Dejana, E., & Risau, W. (1998). Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. Journal of Cell Science, 111(Pt 13), 1853-1865.
130. Lee, T. H., Avraham, H. K., Jiang, S., & Avraham, S. (2003). Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. Journal of Biological Chemistry, 278, 5277-5284.
131. Kevil, C. G., Payne, D. K., Mire, E., & Alexander, J. S. (1998). Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. Journal of Biological Chemistry, 273, 15099-15103.
132. Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996). Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proceedings of the National Academy of Sciences of the United States of America, 93, 14765-14770.
133. Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004). Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Research, 64, 3731-3736.
134. Lee, C. G., Heijn, M., di Tomaso, E., Griffon-Etienne, G., Ancukiewicz, M., Koike, C., et al. (2000). Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Research, 60, 5565-5570.
135. Salnikov, A. V., Heldin, N. E., Stuhr, L. B., Wiig, H., Gerber, H., Reed, R. K., et al. (2006). Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. International Journal of Cancer, 119, 2795-2802.
136. Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., et al. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine, 10, 145-147.
137. Weis, S., Cui, J., Barnes, L., & Cheresh, D. (2004). Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. Journal of Cell Biology, 167, 223-229.
138. Rofstad, E. K., & Danielsen, T. (1999). Hypoxia-induced metastasis of human melanoma cells: Involvement of vascular endothelial growth factor-mediated angiogenesis. British Journal of Cancer, 80, 1697-1707.
139. Melnyk, O., Shuman, M. A., & Kim, K. J. (1996). Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Research, 56, 921-924.
140. Chambers, A. F., MacDonald, I. C., Schmidt, E. E., Koop, S., Morris, V. L., Khokha, R., et al. (1995). Steps in tumor metastasis: New concepts from intravital videomicroscopy. Cancer Metastasis Reviews, 14, 279-301.
141. Cuvier, C., Jang, A., & Hill, R. P. (1997). Exposure to hypoxia, glucose starvation and acidosis: Effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Clinical & Experimental Metastasis, 15, 19-25.
142. Postovit, L. M., Adams, M. A., Lash, G. E., Heaton, J. P., & Graham, C. H. (2004). Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis. International Journal of Cancer, 108, 47-53.
143. Liotta, L. A., Kleinerman, J., & Saidel, G. M. (1974). Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Research, 34, 997-1004.
144. Butler, T. P., & Gullino, P. M. (1975). Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Research, 35, 512-516.
145. Morris, V. L., Koop, S., MacDonald, I. C., Schmidt, E. E., Grattan, M., Percy, D., et al. (1994). Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth. Clinical & Experimental Metastasis, 12, 357-367.
146. Koop, S., MacDonald, I. C., Luzzi, K., Schmidt, E. E., Morris, V. L., Grattan, M., et al. (1995). Fate of melanoma cells entering the microcirculation: Over 80% survive and extravasate. Cancer Research, 55, 2520-2523.
147. Koop, S., Khokha, R., Schmidt, E. E., MacDonald, I. C., Morris, V. L., Chambers, A. F., et al. (1994). Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Research, 54, 4791-4797.
148. Chambers, A. F., MacDonald, I. C., Schmidt, E. E., Morris, V. L., & Groom, A. C. (2000). Clinical targets for anti-metastasis therapy. Advances in Cancer Research, 79, 91-121.
149. Muir, C., Chung, L. W., Carson, D. D., & Farach-Carson, M. C. (2006). Hypoxia increases VEGF-A production by prostate cancer and bone marrow stromal cells and initiates paracrine activation of bone marrow endothelial cells. Clinical & Experimental Metastasis, 23, 75-86.